Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,098,321 papers from all fields of science
Search
Sign In
Create Free Account
cinepazet
Known as:
Ethyl 4-(3,4,5-Trimethoxycinnamoyl)-1-Piperazineacetate
, 1-Piperazineacetic Acid, 4-(1-Oxo-3-(3,4,5-Trimethoxyphenyl)-2-Propenyl)-, Ethyl Ester
, 4-(1- oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-1- piperazineacetic acid, ethyl ester
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
3 relations
Broader (1)
Piperazines
Narrower (2)
Vascoril
cinepazet maleate
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Synthesis and characterization of piperazineacetic acid-4-methylhydrazine aromatic aldehyde schiff base
Zhou Huilian
2014
Corpus ID: 100645265
Piperazineacetic acid-4-methyl-hydrazine is an important intermediate for Nifurpipone. In order to know the appropriate…
Expand
1980
1980
Cinepazet relaxation of aortic strips from normal and spontaneously hypertensive rats.
J. V. Levy
Research communications in chemical pathology and…
1980
Corpus ID: 36144820
The vasodilator cinepazet (Vascoril) was tested for its ability to relax potassium-contracted aortic strips obtained from normal…
Expand
1980
1980
Cinepazet relaxation of aortic strips from normal and spontaneously hypertensive rats.
Levy Jv
1980
Corpus ID: 99962056
1972
1972
The confirmation in man of the metabolic data for ethyl-4-(3,4,5-trimethoxycinnamoyl)piperazinyl acetate in animals.
L. Chasseaud
,
D. R. Hawkins
,
D. H. Moore
,
D. Hathway
Arzneimittel-Forschung
1972
Corpus ID: 1101791
1972
1972
The confirmation in man of the metabolic data for ethyl-4-(3,4,5-trimethoxycinnamoyl)piperazinyl acetate in animals.
Chasseaud Lf
,
Hawkins Dr
,
Moore Dh
,
Hathway De
1972
Corpus ID: 88649887
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE